Novartis India Limited (NIL), a subsidiary of the Swiss pharmaceutical giant Novartis, has been a significant player in the Indian pharmaceutical landscape since its incorporation in 1947. The company specializes in manufacturing and marketing drugs across four main segments: Pharmaceuticals, Generics, Over-the-Counter, and Animal Health. Over the years, NIL has been involved in several initiatives, including collaborations with the World Health Organization to combat diseases like leprosy and malaria, and launching programs such as JEET to fight tuberculosis.
Noteworthy milestones include the introduction of the drug Glivec in India in 2002 and the establishment of partnerships to enhance their product lines, such as their alliance with Astex Therapeutics for cancer drugs. NIL has also expanded its market presence through strategic agreements, including distribution deals with Nutri-Ad International NV for poultry feed supplements and Johnson and Johnson Limited for veterinary sutures. These developments underscore NIL's commitment to innovation and social responsibility in healthcare.
